Key result
Endothelin receptor blockers can prevent or revert the rise in blood pressure and attenuate proteinuria during angiogenesis inhibition, indicating endothelin-1 as a key mediator.
Why the study?
What is the mechanism underlying the development of hypertension and proteinuria during angiogenesis inhibition?
What is the mechanism underlying the development of hypertension and proteinuria during angiogenesis inhibition?
Answers are grounded in this paper and cite their sources.
Endothelin-1 pathway activation is a key mediator of hypertension and proteinuria induced by VEGF inhibitors, suggesting endothelin receptor blockers as a potential therapeutic strategy.
Angiogenesis inhibition by blocking vascular endothelial growth factor (VEGF)-mediated signalling with monoclonal antibodies or tyrosine kinase inhibitors has become an established treatment of various forms of cancer. This treatment is frequently associated with the development of hypertension and proteinuria. As VEGF increases the expression and the activity of nitric oxide synthase in endothelial cells, a decrease in the bioavailability of nitric oxide has been proposed as a key mechanism leading to hypertension during angiogenesis inhibition. However, results of clinical and experimental studies exploring this possibility are conflicting. Rarefaction, that is a structural decrease of microcirculatory vessels, has been reported during antiangiogenic treatment, but evidence that it plays a role in development of hypertension is lacking. Elevated circulating and urinary levels of endothelin-1 have been observed in clinical and experimental studies with angiogenesis inhibitors. Furthermore, the observation that endothelin receptor blockers can prevent or revert the rise in blood pressure during angiogenesis inhibition and attenuate proteinuria provides strong evidence that an activated endothelin-signalling pathway is a final common mediator of angiogenesis inhibition-induced rise in blood pressure and renal toxicity.
No takes yet. Share an insight, caveat, or question.
Lankhorst et al. (2012) conducted a review in Hypertension and proteinuria during angiogenesis inhibition. Angiogenesis inhibitors (VEGF blockers) was evaluated. Endothelin receptor blockers can prevent or revert the rise in blood pressure and attenuate proteinuria during angiogenesis inhibition, indicating endothelin-1 as a key mediator.
Synapse has enriched 10 related papers. Consider them for comparative context: